Abbott Kaletra Tops 12% Of PI Market; Synthroid Outlook Is "Very Good"
Executive Summary
Abbott expects to claim the number one spot in the protease inhibitor market by the end of 2001 on the strength of the first-year performance of Kaletra (ritonavir/lopinavir).